BIOMAT Database Logo BIOMAT Database Logo

Advances in Rejection Management: Prevention and Treatment. 2021

Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Department of Medicine, Northwestern University Feinberg School of Medicine, 676 North St. Clair Street, Suite 2330, Chicago, IL 60611, USA.

Extended survival of liver transplant recipients has brought rejection management to the forefront of liver transplant research. This article discusses T-cell-mediated rejection, antibody-mediated rejection, and chronic rejection. We focus on the prevention and then discuss treatment options. Future directions of rejection management include biomarkers of rejection, which may allow for monitoring of patients who are considered high risk for rejection and detection of rejection before there is any clinical evidence to improve graft and patient survival. With improved graft life and survival of liver transplant recipients, the new frontier of rejection management focuses on immunosuppression minimization, withdrawal, and personalization.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D016031 Liver Transplantation The transference of a part of or an entire liver from one human or animal to another. Grafting, Liver,Hepatic Transplantation,Liver Transplant,Transplantation, Hepatic,Transplantation, Liver,Hepatic Transplantations,Liver Grafting,Liver Transplantations,Liver Transplants,Transplant, Liver

Related Publications

Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Advances in diagnosis, prevention, and management of hepatic allograft rejection.
November 1994, Clinical chemistry,
Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention.
August 2001, Expert review of anticancer therapy,
Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Advances in the prevention, management, and treatment of community-acquired pneumonia.
January 2016, F1000Research,
Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Advances in the prevention, management, and treatment of community-acquired pneumonia.
July 2010, F1000 medicine reports,
Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Management and prevention of corneal graft rejection.
September 2023, Indian journal of ophthalmology,
Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Preterm birth: advances in prevention management.
December 2004, Seminars in fetal & neonatal medicine,
Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Antibody-mediated rejection: New approaches in prevention and management.
January 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Advances in vasospasm treatment and prevention.
October 2007, Journal of the neurological sciences,
Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Recent advances in immunosuppressive therapy for prevention of renal allograft rejection.
August 2011, Current opinion in organ transplantation,
Claire R Harrington, and Guang-Yu Yang, and Josh Levitsky
Recent advances in antifungal prevention and treatment.
July 2009, Seminars in hematology,
Copied contents to your clipboard!